Cargando…

Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling

SIMPLE SUMMARY: Breast cancer patients often receive anti-hormonal treatment if their tumor is positive for the Estrogen Receptor (ER), but tumors may become resistant to this therapy and still metastasize. We studied 101 of such metastatic lesions and investigated these lesions for mutated genes an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angus, Lindsay, Smid, Marcel, Wilting, Saskia M., Bos, Manouk K., Steeghs, Neeltje, Konings, Inge R. H. M., Tjan-Heijnen, Vivianne C. G., van Riel, Johanna M. G. H., van de Wouw, Agnes J., Cuppen, Edwin, Lolkema, Martijn P., Jager, Agnes, Sleijfer, Stefan, Martens, John W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487136/ https://www.ncbi.nlm.nih.gov/pubmed/37686693 http://dx.doi.org/10.3390/cancers15174416

Ejemplares similares

Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
por: Mendelaar, Pauline A. J., et al.
Publicado: (2021)

Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
por: Mendelaar, Pauline A. J., et al.
Publicado: (2021)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022)

A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients
por: Jongbloed, Elisabeth M., et al.
Publicado: (2021)

Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progression
por: Bos, Manouk K., et al.
Publicado: (2022)

Pan-cancer whole-genome analyses of metastatic solid tumours
por: Priestley, Peter, et al.
Publicado: (2019)

The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches
por: Lobbezoo, Dorien, et al.
Publicado: (2016)

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
por: Verschoor, Noortje, et al.
Publicado: (2023)

Lost by Transcription: Fork Failures, Elevated Expression, and Clinical Consequences Related to Deletions in Metastatic Colorectal Cancer
por: Smid, Marcel, et al.
Publicado: (2022)

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
por: Kruger, Dinja T., et al.
Publicado: (2020)

Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
por: Seferina, Shanly C., et al.
Publicado: (2017)

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry
por: Claessens, Anouk K. M., et al.
Publicado: (2020)

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
por: van Dessel, Lisanne F., et al.
Publicado: (2019)

Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting
por: Bos, Manouk K., et al.
Publicado: (2023)

A tale on rabbit ears and pan-handles, the rings that rule all
por: Smid, Marcel, et al.
Publicado: (2019)

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
por: Jongbloed, Elisabeth M, et al.
Publicado: (2023)

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels
por: Jongbloed, Elisabeth M., et al.
Publicado: (2023)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

High‐throughput isolation of circulating tumor DNA: a comparison of automated platforms
por: van Dessel, Lisanne F., et al.
Publicado: (2018)

Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
por: van Abbema, Doris, et al.
Publicado: (2019)

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
por: Jiao, Wei, et al.
Publicado: (2020)

Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
por: Jiao, Wei, et al.
Publicado: (2022)

High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments
por: Deger, Teoman, et al.
Publicado: (2021)

The mutational footprints of cancer therapies
por: Pich, Oriol, et al.
Publicado: (2019)

Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands
por: Schneider, Paul Peter, et al.
Publicado: (2021)

What to Do with Non-visualized Sentinel Nodes? A Dutch Nationwide Survey Study
por: Verheuvel, Nicole C., et al.
Publicado: (2017)

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material
por: de Leng, Wendy W. J., et al.
Publicado: (2016)

Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure
por: Verheuvel, Nicole C., et al.
Publicado: (2017)

Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients
por: van den Berg, Inge, et al.
Publicado: (2021)

Development of indicators for patient-centred cancer care
por: Ouwens, Mariëlle, et al.
Publicado: (2009)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
por: Bijlsma, Rhode, et al.
Publicado: (2020)

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer
por: Guman, Noori A. M., et al.
Publicado: (2021)

A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer
por: van den Berg, Inge, et al.
Publicado: (2021)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors
por: Truin, Wilfred, et al.
Publicado: (2017)

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study
por: Weeber, Fleur, et al.
Publicado: (2017)

Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity
por: Wang, Boshi, et al.
Publicado: (2022)

Frequency and diagnostic outcome of bilateral recall at screening mammography
por: Lameijer, Joost R. C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tekrd1b2nj4tovnaaop28otd4o